lupus

When flushing is more than embarrassmentAcute or irregular flushing may signal a more serious health condition, say researchers who list 14 questions physicians should ask patients complaining about unusual flushing.
Seven diseases benefiting from genetic tests
Seven diseases benefiting from genetic testsGenetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.
Systemic conditions that can affect skinSkin can act as a window to a patient’s general health says a physician writing in the journal Medicine. Changes in the skin can signal underlying disease from lupus to gastrointestinal disease.
Skin lupus can progress more rapidly than previously thoughtSystemic disease among patients with discoid lupus erythematosus, a chronic form of cutaneous lupus, can develop within one to two years of initial diagnosis, says Joseph F. Merola, M.D., reporting at the American Academy of Dermatology annual meeting in San Diego.
Survey uncovers lupus corticosteroid treatment issuesPatients with systemic lupus erythematosus often self-manage their corticosteroid medication without the consent of their healthcare providers, according to a recent multicountry survey.
New challenges, opportunities in autoimmune disease treatment
New challenges, opportunities in autoimmune disease treatmentAllegheny Health Network’s Susan Manzi, MD, MPH, discusses the healthcare needs of patients with lupus and other autoimmune disorders.
Rheumatology for the dermatologist
Rheumatology for the dermatologistThe signs and symptoms of some dermatologic and rheumatologic diseases sometimes overlap, and a better understanding of their associations and subsequent clinical and laboratory evaluations can help in optimizing the treatment and management of this patient population.
NIH partners with industry to find best biological targets of diseaseThe National Institutes of Health, FDA, 10 biopharmaceutical companies, the Pharmaceutical Research and Manufacturers of America, and several nonprofit organizations have launched an unprecedented public/private partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.
Pharma, government, and nonprofit organizations unite in search for new therapiesThe National Institutes of Health (NIH), FDA, 10 biopharmaceutical companies, the Pharmaceutical Research and Manufacturers of America, and several nonprofit organizations have launched an unprecedented public/private partnership to “transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets of disease,” announced a recent statement from the NIH.